BOREALIS BIOSCIENCES
Live / Applied — First extension granted (statement of use) (as of 04 Feb 2026)
What this means for you
Not registered yet, but its 15 Oct 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98801942
- Mark type
- Stylized text
- Filed
- 15 Oct 2024
- Published for opposition
- 01 Jul 2025
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, biological preparations, and clinical medical reagents for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders
Owner
- Borealis Biosciences, Inc., San Francisco, CA, US
- Borealis Biosciences, Inc., San Francisco, CA, US
Prosecution history
- 04 Feb 2026 — SOU EXTENSION 1 GRANTED
- 04 Feb 2026 — SOU EXTENSION 1 FILED
- 04 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 26 Aug 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 01 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Jul 2025 — PUBLISHED FOR OPPOSITION
- 25 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 29 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 May 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 22 May 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 22 May 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 25 Mar 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 25 Mar 2025 — NON-FINAL ACTION E-MAILED
- 25 Mar 2025 — NON-FINAL ACTION WRITTEN
- 24 Mar 2025 — ASSIGNED TO EXAMINER